Concord Biotech Limited (NSEI: CONCORDBIO)
Health Care · Pharmaceuticals · IN
Rs1,361.40
-0.92% today · -13.0% 1Y
Concord Biotech Limited (NSEI: CONCORDBIO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.47B and employs 1,624 people.
Over the last twelve months the share price has lost 13.0%, trading between 987.00 and 1.63K.
Tweenvest scores Concord Biotech Limited across four factors: quality 87/100, value 51/100, growth 65/100, dividend 49/100. Its strongest factor is quality.
CONCORDBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.47B
- Revenue (TTM)
- $117.23M
- P/E
- 51.89
- EPS
- 26.24
- Dividend yield
- 0.55%
- Beta (5Y)
- 0.37
- 52-week high
- Rs1,627.00
- 52-week low
- Rs987.00
- Avg volume (3M)
- —
- Shares outstanding
- 104.62M
- Employees
- 1,624
- Next earnings
- —
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
- ISIN
- INE338H01029
- Founded
- 1984
- Listed since
- Aug 18, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Yifan Pharmaceutical Co., Ltd.SZSE: 002019 | $1.50B | CN¥9.66 | +2.55% |
| Tianjin Chase Sun Pharmaceutical Co.,LtdSZSE: 300026 | $1.49B | CN¥3.32 | +2.15% |
| Jiangxi Fushine Pharmaceutical Co., Ltd.SZSE: 300497 | $1.48B | CN¥18.43 | +3.19% |
| Mayinglong Pharmaceutical Group Co., Ltd.SHSE: 600993 | $1.48B | CN¥22.95 | +1.91% |
| Rapport Therapeutics, Inc.NasdaqGM: RAPP | $1.47B | $30.65 | -4.72% |
| Zhejiang Hisoar Pharmaceutical Co., Ltd.SZSE: 002099 | $1.46B | CN¥6.32 | +2.76% |
| NATCO Pharma LimitedNSEI: NATCOPHARM | $1.46B | Rs789.40 | -3.88% |
| Zhejiang Jingxin Pharmaceutical Co., Ltd.SZSE: 002020 | $1.45B | CN¥11.87 | +0.34% |
Figures last refreshed Oct 11, 2026.